Should I buy or sell BioRestorative Therapies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares. View BRTX analyst ratings or view top-rated stocks .

What is BioRestorative Therapies' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 729.0% from the stock's current price. View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts .

How have BRTX shares performed in 2023?

BioRestorative Therapies' stock was trading at $2.75 at the start of the year. Since then, BRTX shares have decreased by 34.2% and is now trading at $1.8094. View the best growth stocks for 2023 here .

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX) , Sierra Oncology (SRRA) , Tonix Pharmaceuticals (TNXP) , Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , Actinium Pharmaceuticals (ATNM) , Inpixon (INPX) and OPKO Health (OPK) .

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

BioRestorative Therapies Stock Price, News & Analysis (OTCMKTS:BRTX)

$1.81

+0.05 (+2.84%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.70
▼
$1.89
50-Day Range: $1.58
▼
$2.28
52-Week Range: $1.41
▼
$7.13

Volume: 16,542 shs
Average Volume: 191,954 shs
Market Capitalization: $8.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BRTX Stock News Headlines

November 9, 2023 | cnet.com

Best Light Therapy Lamps for 2023

October 9, 2023 | finance.yahoo.com

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

December 7, 2023 | Edge On The Street (Ad)

Henry Ford Would NEVER Have Seen This Coming

In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.

September 18, 2023 | seekingalpha.com

BioRestorative Therapies' 10% shareholder Broadrick Dale increases holding

September 18, 2023 | finance.yahoo.com

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

September 12, 2023 | finanznachrichten.de

BioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

September 12, 2023 | stockhouse.com

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

September 8, 2023 | finance.yahoo.com

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

December 7, 2023 | Edge On The Street (Ad)

Henry Ford Would NEVER Have Seen This Coming

August 30, 2023 | msn.com

$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

August 29, 2023 | benzinga.com

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

August 15, 2023 | msn.com

Roth MKM Reiterates BioRestorative Therapies (BRTX) Buy Recommendation

August 8, 2023 | finance.yahoo.com

Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates

July 27, 2023 | msn.com

$BRTX: Insights From A Specialist On Stem Cell-Based Therapies And The Need For Spinal Care Reform

July 27, 2023 | finance.yahoo.com

Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)

July 21, 2023 | finanznachrichten.de

BioRestorative Therapies, Inc.: BioRestorative Therapies Receives Landmark License From New York State

July 21, 2023 | finance.yahoo.com

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

July 18, 2023 | msn.com

$BRTX's Drug Candidate BRTX-100 Excels In Safety Test, Advances To Phase 2 And Expands Pipeline

July 11, 2023 | msn.com

Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered

July 11, 2023 | finance.yahoo.com

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

July 7, 2023 | finance.yahoo.com

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

June 27, 2023 | benzinga.com

EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease To Continue Unchanged

June 27, 2023 | finance.yahoo.com

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

June 27, 2023 | finance.yahoo.com

EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged

June 26, 2023 | finance.yahoo.com

BioResorative CEO is Featured in An Interview With SmallCaps Daily

June 17, 2023 | finance.yahoo.com

Is BioRestorative Therapies (NASDAQ:BRTX) In A Good Position To Invest In Growth?

June 16, 2023 | finance.yahoo.com

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

See More Headlines

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BRTX
CUSIP: N/A
CIK: 1505497
Web: www.biorestorative.com
Phone: (631) 760-8100
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +729.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,500,000.00
Net Margins: -13,728.83%
Pretax Margin: -13,728.83%
Return on Equity: -120.47%
Return on Assets: -114.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.81
Quick Ratio: 14.81

Sales & Book Value

Annual Sales: $130,200.00
Price / Sales: 65.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.65 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 4,707,000
Free Float: 3,660,000
Market Cap: $8.52 million
Optionable: Not Optionable
Beta: 58.92

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Lance Alstodt (Age 52)
Chairman of the Board, President & CEO
Comp: $400k
Mr. Robert Eugene Kristal (Age 55)
Chief Financial Officer
Comp: $175k
Mr. Francisco J. Silva (Age 48)
Chief Scientist, VP of Research & Development, Secretary and Director
Comp: $375k
Mr. Robert Paccasassi (Age 54)
Vice President of Quality Assurance & Regulatory Compliance
Comp: $233.95k
Dr. Wayne J. Olan M.D.
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings or view top-rated stocks.
What is BioRestorative Therapies' stock price target for 2024?: 1 Wall Street research analysts have issued 12-month price objectives for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 729.0% from the stock's current price.
View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts.
How have BRTX shares performed in 2023?: BioRestorative Therapies' stock was trading at $2.75 at the start of the year. Since then, BRTX shares have decreased by 34.2% and is now trading at $1.8094.
View the best growth stocks for 2023 here.
How were BioRestorative Therapies' earnings last quarter?: BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?: BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
What other stocks do shareholders of BioRestorative Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).
How do I buy shares of BioRestorative Therapies?: Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BRTX) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial